Ovid Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated June 11, 2021, reports the results of the Annual Meeting of Stockholders held on June 10, 2021. Ovid Therapeutics Inc. is a Delaware corporation with its principal executive offices in New York, New York, and its common stock trades on The Nasdaq Stock Market LLC under the symbol "OVID".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1 (Election of Director): Barbara Duncan was elected as a director for a three-year term. The vote tally was 27,065,759 votes For, 6,894,669 votes Withheld, and 19,036,051 Broker Non-Votes.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021. The vote tally was 52,384,946 votes For, 483,586 votes Against, and 127,947 votes Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Barbara Duncan was successfully elected to the Board of Directors.
- KPMG LLP was ratified as the independent auditor for the 2021 fiscal year.
- A significant number of shares (19,036,051) were recorded as Broker Non-Votes for the director election.
- Details regarding the proposals are described in the definitive proxy statement filed on April 30, 2021.